Multiple cell, animal, and small human studies converge on a striking finding: lactoferrin directly stimulates osteoblast proliferation and inhibits osteoclast formation. Doses of 250-1000 mg/day improve markers of bone formation and may complement standard osteoporosis therapy.
Osteoporosis affects roughly 200 million people globally and is responsible for over 8.9 million fractures annually. Standard treatments — bisphosphonates, denosumab, romosozumab, teriparatide — work but have well-known limitations: jaw osteonecrosis risk, atypical femur fractures, rebound bone loss after discontinuation, and high cost.
A growing body of cell, animal, and human research suggests bovine lactoferrin has direct, dual-mechanism bone-positive effects: it stimulates osteoblast proliferation and survival while inhibiting osteoclast formation. The clinical evidence is still developing, but mechanistically and from preliminary human data, lactoferrin deserves consideration as a complementary intervention for bone health.
Lactoferrin's bone-positive effects work through multiple pathways:
Lactoferrin binds to the LRP1 receptor on osteoblasts and activates the MAPK / ERK and PI3K / Akt signaling pathways. The result is:
Lactoferrin also acts directly on osteoclast precursors: